| Abstrakt: |
A recent study conducted by researchers at Hokkaido University of Science in Sapporo, Japan, has shed light on the potential mechanism behind diarrhea caused by certain cancer treatments. The study focused on the use of epidermal growth factor receptor tyrosine kinase inhibitors (EGFR-TKIs) in the treatment of non-small cell lung cancer. The researchers found that EGFR-TKIs can affect chloride channels in the intestines, leading to diarrhea. They also discovered that a specific protein called alpha-defensin 5 (DEFA5) plays a significant role in this process. This research provides valuable insights into the potential host action of DEFA5 in cancer therapy. [Extracted from the article] |
